Arrival & Registration

Networking breakfast for all attendees.

Welcome from STAT

Opening Remarks

Will the Doctor GPT You Now?

Microsoft has emerged as a leading player in generative AI, including in health care. The first big foray is in note-taking. But how else could large language models help doctors do their jobs?

NVIDIA Takes On One of the World’s Biggest Challenges: Inventing Drugs

Few human endeavors are as beset by expensive failure as the quest to develop drugs – and new technologies rarely move the needle. Will generative AI be different? Hear the case for “yes.”

How AI Can Help Us Make Better Medicines

We’re in an unprecedented time where computational methods, especially from AI/Machine Learning, are becoming just as essential as biology and chemistry to the future of medicines. Genentech is pioneering a strategy called the “Lab in a Loop” – an iterative cycle of data, computation, experimentation, and discovery – that is accelerating and improving drug discovery and development.

Going Deeper into Using Generative AI to Design Drugs

In developing AlphaFold, Google DeepMind solved one of the enduring grand challenges of computational biology — predicting the 3D structure of proteins from their amino acid sequences. The next test is turning that fundamental breakthrough into a business that can help pharma develop new medicines. Here’s a closer look at how it’s going.

Grasping the Genome’s Grammar

The ARC Institute represents a new approach to a research institute, bridging academia and industry. Hear how some of the results there could change the way that researchers understand and manipulate DNA.

Ranking Drug Companies on Innovation and Invention

IDEA Pharma unveils the 13th annual edition of its ranking of the companies that do the best jobs creating medicines and bringing them to market.

COFFEE BREAK

The Opioid Crisis: Harm Reduction vs. Harm

In a bid to decrease opioid deaths, the U.S. has increasingly embraced harm reduction tactics like syringe exchange and fentanyl test strips. But the approach is now facing major resistance even in historically progressive cities. If harm reduction works, why is it so unpopular? We’ll look at the data, the politics, and the response to the drug crisis in San Francisco and across the country.

The Long View on Health Care: The Change Hack, AI Bets & Health Tech’s Future

A key architect of the Affordable Care Act is now one of tech’s most influential investors. Hear Bob Kocher reflect on this year’s biggest news: the Change Healthcare attack, the explosion of generative AI startups vying for investor dollars, and the future of digital health – and see what he thinks will be coming up next for health care startups.

How Artificial Intelligence is Powering the Future of Biomedical Science

Artificial intelligence (AI) has enormous potential to accelerate the pace of science and medicine. The Chan Zuckerberg Initiative (CZI) is building and funding one of the largest AI computing systems for nonprofit life science research in the world to enable virtual cell models that are capable of predicting the behavior of healthy and diseased cells. Explore how AI-powered virtual cell models will help scientists unlock the molecular underpinnings of human health and disease.

Science’s New Watchdogs

The discovery of reused or altered images in scientific papers is shining a bright and uncomfortable spotlight on the research world, leading to a string of retracted papers and even some surprising resignations. Meet two key figures in this major scientific moment for a tough discussion about what is coming next.

LUNCH

Can AI Fix Medical Documentation?

One of the nearest benefits from artificial intelligence in medicine could be keeping better track of conversations between patients and doctors – without forcing the doctor to hunch over the electronic medical record. See this play out live.

The STAT Startup Panel

Come hear from three of the most interesting new companies in the health care universe – bridging drug development, health tech, and more. Find out the next targets for medical entrepreneurs.

Ending the HIV Epidemic – Our Path Toward a Cure

For 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. From the first single-tablet regimen to treat HIV to the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections and now to the first long-acting injectable HIV treatment medication administered twice-yearly – our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. As we forge ahead on the path to a cure, here’s how we aim to address the most pressing needs of the day and keep people impacted by HIV at the center of all that we do.

Can Health Tech Combat Black Maternal Mortality?

Black maternal mortality is nearly triple the rate for white women. These startups are trying to reduce this awful disparity, helping pregnant people avoid subpar hospitals, connect with doulas, and track health metrics.

Can Wearables Still Upend Medicine?

It’s been almost a decade since the Apple Watch started to catalyze a new interest in using wearables for medical diagnosis. But hype has met reality all too often. What is next, and what role should industry and academia play in changing how our devices monitor us?

COFFEE BREAK

A Biotech With Heart

The story of Cytokinetics is one of perseverance, stubbornness, and setbacks overcome. Founded in 1997 to exploit emerging science in muscle biology, the company is finally on the cusp of its first drug approval for aficamten, a treatment for an inherited form of heart disease. Retrace the bumpy road to this triumphant moment and look toward the future with the company’s long-time CEO.

Setting Expectations for AI In Drug Development

The advent of generative AI means hopes for advances in drug development have never been higher. What is realistic? What is not?

Closing Remarks

Closing from STAT

Networking Reception

Open to all summit attendees.